200 related articles for article (PubMed ID: 35538822)
1. Evaluation of the Effect of Chelating Arms and Carrier Agents on t he Radiotoxicity of TAT Agents.
Farzipour S; Shaghaghi Z; Raeispour M; Alvandi M; Jalali F; Yazdi A
Curr Radiopharm; 2023; 16(1):2-22. PubMed ID: 35538822
[TBL] [Abstract][Full Text] [Related]
2. Targeted alpha therapy: part I.
Elgqvist J
Curr Radiopharm; 2011 Jul; 4(3):176. PubMed ID: 22201706
[TBL] [Abstract][Full Text] [Related]
3. Alpha-emitters for immuno-therapy: a review of recent developments from chemistry to clinics.
Huclier-Markai S; Alliot C; Varmenot N; Cutler CS; Barbet J
Curr Top Med Chem; 2012; 12(23):2642-54. PubMed ID: 23339760
[TBL] [Abstract][Full Text] [Related]
4. Radiotoxicity of alpha particles versus high and low energy electrons in hypoxic cancer cells.
Maucksch U; Runge R; Oehme L; Kotzerke J; Freudenberg R
Nuklearmedizin; 2018 Apr; 57(2):56-63. PubMed ID: 29590676
[TBL] [Abstract][Full Text] [Related]
5. Dosimetry in targeted alpha therapy. A systematic review: current findings and what is needed.
Tronchin S; Forster JC; Hickson K; Bezak E
Phys Med Biol; 2022 Apr; 67(9):. PubMed ID: 35316802
[No Abstract] [Full Text] [Related]
6. MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.
Sgouros G; Roeske JC; McDevitt MR; Palm S; Allen BJ; Fisher DR; Brill AB; Song H; Howell RW; Akabani G; ; Bolch WE; Brill AB; Fisher DR; Howell RW; Meredith RF; Sgouros G; Wessels BW; Zanzonico PB
J Nucl Med; 2010 Feb; 51(2):311-28. PubMed ID: 20080889
[TBL] [Abstract][Full Text] [Related]
7. Development of Targeted Alpha Particle Therapy for Solid Tumors.
Tafreshi NK; Doligalski ML; Tichacek CJ; Pandya DN; Budzevich MM; El-Haddad G; Khushalani NI; Moros EG; McLaughlin ML; Wadas TJ; Morse DL
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779154
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry and Radiobiology of Alpha-Particle Emitting Radionuclides.
Sgouros G; Hobbs R; Josefsson A
Curr Radiopharm; 2018; 11(3):209-214. PubMed ID: 29697036
[TBL] [Abstract][Full Text] [Related]
9. Targeted Alpha Therapy: Current Clinical Applications.
Guerra Liberal FDC; O'Sullivan JM; McMahon SJ; Prise KM
Cancer Biother Radiopharm; 2020 Aug; 35(6):404-417. PubMed ID: 32552031
[TBL] [Abstract][Full Text] [Related]
10. Cancer radioimmunotherapy with alpha-emitting nuclides.
Couturier O; Supiot S; Degraef-Mougin M; Faivre-Chauvet A; Carlier T; Chatal JF; Davodeau F; Cherel M
Eur J Nucl Med Mol Imaging; 2005 May; 32(5):601-14. PubMed ID: 15841373
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic radionuclides: production and decay property considerations.
Volkert WA; Goeckeler WF; Ehrhardt GJ; Ketring AR
J Nucl Med; 1991 Jan; 32(1):174-85. PubMed ID: 1988628
[TBL] [Abstract][Full Text] [Related]
12. Radioimmunotherapy with α-particle-emitting radionuclides.
Seidl C
Immunotherapy; 2014; 6(4):431-58. PubMed ID: 24815783
[TBL] [Abstract][Full Text] [Related]
13. Solid-tumor radionuclide therapy dosimetry: new paradigms in view of tumor microenvironment and angiogenesis.
Zhu X; Palmer MR; Makrigiorgos GM; Kassis AI
Med Phys; 2010 Jun; 37(6):2974-84. PubMed ID: 20632610
[TBL] [Abstract][Full Text] [Related]
14. Pretargeted radioimmunotherapy with α-particle emitting radionuclides.
Lindegren S; Frost SH
Curr Radiopharm; 2011 Jul; 4(3):248-60. PubMed ID: 22201711
[TBL] [Abstract][Full Text] [Related]
15. An overview of targeted alpha therapy.
Kim YS; Brechbiel MW
Tumour Biol; 2012 Jun; 33(3):573-90. PubMed ID: 22143940
[TBL] [Abstract][Full Text] [Related]
16. Bismuth-213 and actinium-225 -- generator performance and evolving therapeutic applications of two generator-derived alpha-emitting radioisotopes.
Morgenstern A; Bruchertseifer F; Apostolidis C
Curr Radiopharm; 2012 Jul; 5(3):221-7. PubMed ID: 22642390
[TBL] [Abstract][Full Text] [Related]
17. Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
Lee D; Li M; Bednarz B; Schultz MK
Radiat Res; 2018 Sep; 190(3):236-247. PubMed ID: 29944461
[TBL] [Abstract][Full Text] [Related]
18. Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy.
Hobbs RF; Howell RW; Song H; Baechler S; Sgouros G
Radiat Res; 2014 Jan; 181(1):90-8. PubMed ID: 24502376
[TBL] [Abstract][Full Text] [Related]
19. Which radionuclide, carrier molecule and clinical indication for alpha-immunotherapy?
Guerard F; Barbet J; Chatal JF; Kraeber-Bodere F; Cherel M; Haddad F
Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):161-7. PubMed ID: 25752501
[TBL] [Abstract][Full Text] [Related]
20. Targeted alpha therapy with 213Bi.
Morgenstern A; Bruchertseifer F; Apostolidis C
Curr Radiopharm; 2011 Oct; 4(4):295-305. PubMed ID: 22202152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
